These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7020916)

  • 1. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.
    Hill GJ; Moss SE; Golomb FM; Grage TB; Fletcher WS; Minton JP; Krementz ET
    Cancer; 1981 Jun; 47(11):2556-62. PubMed ID: 7020916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
    Balch CM; Murray D; Presant C; Bartolucci AA
    Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
    Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma.
    Costanza ME; Nathanson L; Costello WG; Wolter J; Brunk SF; Colsky J; Hall T; Oberfield RA; Regelson W
    Cancer; 1976 Apr; 37(4):1654-9. PubMed ID: 769936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    Presant CA; Bartolucci AA; Smalley RV; Vogler WR
    Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    Robidoux A; Gutterman JU; Bodey GP; Hersh EM
    Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation.
    Thatcher N; Anderson H; James R; Davenport P; Craig P
    Cancer; 1986 Jun; 57(11):2103-7. PubMed ID: 3697910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
    Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).
    Baker LH; Frank J; Fine G; Balcerzak SP; Stephens RL; Stuckey WJ; Rivkin S; Saiki J; Ward JH
    J Clin Oncol; 1987 Jun; 5(6):851-61. PubMed ID: 3295129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC; Cosimi AB; Carey RW; Kaufman SD
    Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
    Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
    J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441).
    Taylor SG; Nelson L; Baxter D; Rosenbaum C; Sponzo RW; Cunningham TJ; Olson KB; Horton J
    Cancer; 1975 Oct; 36(4):1269-76. PubMed ID: 169984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
    Chang CH; Horton J; Schoenfeld D; Salazer O; Perez-Tamayo R; Kramer S; Weinstein A; Nelson JS; Tsukada Y
    Cancer; 1983 Sep; 52(6):997-1007. PubMed ID: 6349785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
    Huncharek M; Caubet JF; McGarry R
    Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
    Abdi EA; Hanson J; McPherson TA
    Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
    Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
    Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma.
    Gill A; Gosain R; Gragg H; Bycroft R; Rai SN; Pan J; Chesney JA; Miller DM
    Am J Med Sci; 2019 Jan; 357(1):43-48. PubMed ID: 30611319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
    Hill GJ; Krementz ET; Hill HZ
    Cancer; 1984 Mar; 53(6):1299-305. PubMed ID: 6362841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.